The Company also announced that after receiving regulatory approvals in additional countries, it has expanded the commercialization of the TAXUS product through the WISDOM transitional registry program. Boston Scientific is conducting the registry in a number of countries as part of a limited commercial launch.

"We continue to make solid progress on a number of fronts with our TAXUS program, and the application for CE Mark is further evidence that we are on track to launch in Europe later this year," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "The medical community is responding positively to the transitional approach of the WISDOM registry, because it allows physicians, providers and payers to work together to responsibly introduce this promising new technology. The TAXUS program continues to click off milestones on its way to realizing its potential as a safe and effective new treatment for coronary artery disease."

The TAXUS program is a series of clinical studies designed to collect data on Boston Scientific's proprietary paclitaxel-eluting stent technology for reducing coronary restenosis, the growth of tissue within an artery after angioplasty and stenting. Paclitaxel, the active component of the popular chemotherapeutic agent Taxol®, has demonstrated promising results in pre-clinical and clinical studies for reducing the processes leading to restenosis.

The TAXUS I trial confirmed safety and reported zero thrombosis and zero restenosis. The TAXUS II trial completed enrollment of 537 patients in January, and the patients are now in the follow-up period. Preliminary safety data from TAXUS II presented in March at the American College of Cardiology annual meeting provided further support for the safety of paclitaxel-eluting stents. The TAXUS III trial studied the treatment of in-stent restenosis and also confirmed safety with no thrombosis. The TAXUS IV trial has enrolled 1,172 patients, the target patient number for the trial, and the follow-up period has begun for those patients.

Boston Scientific plans to launch paclitaxel-eluting stents in Europe this year and in the U.S. in 2003.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The Company's products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, physician acceptance of new products, competitive product offerings and other factors described in the Company's filings with the Securities and Exchange Commission.